American Cryostem

American Cryostem EBIT per Share

Delisted

The EBIT per Share of American Cryostem (CRYO) as of Nov 11, 2026 is -0.05 USD. In the previous year, EBIT per Share was -0.02 USD — a change of 161.24% (lower).

EBIT per Share

-0.05USD

YoY

161.24%

Last updated:

EBIT per Share of American Cryostem is 2021 -0.05 USD. EBIT per Share of American Cryostem was 2020 -0.02 USD. It decreases by 161.24% lower compared to the previous year.

The American Cryostem EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2014
-0.06 USD
Jan 1, 2015
-0.04 USD
Jan 1, 2016
-0.04 USD
Jan 1, 2017
-0.03 USD
Jan 1, 2018
-0.03 USD
Jan 1, 2019
-0.02 USD
Jan 1, 2020
-0.02 USD
Jan 1, 2021
-0.05 USD
The American Cryostem EBIT per Share history
YEAREBIT per ShareYoY
-0.05USD+161.24%
-0.02USD-10.34%
-0.02USD-27.55%
-0.03USD-0.11%
-0.03USD-25.53%
-0.04USD-0.21%
-0.04USD-37.62%
-0.06USD-19.43%
-0.07USD-16.19%
-0.09USD-0.93%
-0.09USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Cryostem Stock analysis

What does American Cryostem do? American Cryostem Corporation (ACC) is a biotechnology company based in New Jersey that specializes in the development of stem cell products. The company was founded in 2008 and went public in the same year. ACC utilizes cutting-edge technologies to isolate, expand, store, and transport human stem cells. The company offers a wide range of stem cell products and services, with applications in regenerative medicine, cosmetics, sports medicine, and biomedical research. ACC collaborates with academic research institutions, biomedical companies, and clinical facilities to enable innovations in stem cell research. The company has a close partnership with Rutgers University in New Jersey, one of the leading research institutions in the field of stem cell research. The products and services of American Cryostem Corp include a variety of stem cell products and services, such as isolation of stem cells from adipose tissue, expansion of stem cells, cryopreservation of stem cells, and tissue and organ regeneration. The business model of American Cryostem Corp is based on the utilization of stem cells derived from human adipose tissue. The company uses advanced technologies to isolate, expand, store, and transport these stem cells. The stem cell products can be used in medicine, cosmetics, and biomedical research. One of the key areas of American Cryostem Corp is regenerative medicine. The company develops stem cell therapies for the treatment of various diseases and injuries. American Cryostem Corp has a range of stem cell products that can be used for tissue and organ regeneration. Another focus of American Cryostem Corp is the cosmetics industry. The company offers a wide range of stem cell products for improving skin health and beauty. These products can be used for skin rejuvenation, reducing wrinkles, and improving skin texture. American Cryostem Corp is also active in sports medicine. The company offers stem cell products that can be used in the treatment of sports injuries. These products can be used for the regeneration of muscles, tendons, and ligaments. The company is also involved in biomedical research. American Cryostem Corp offers stem cell products and services that can be utilized by academic institutions and biomedical companies for developing new therapies and medications. American Cryostem Corp has a strong innovation capacity and continuously invests in research and development. The company has filed several patents for its technologies and products and is working on the development of new therapies and stem cell products. Overall, American Cryostem Corp is a leading biotechnology company specializing in the development of stem cell products and services. The company has a wide range of products with diverse applications in medicine, cosmetics, sports medicine, and biomedical research. American Cryostem Corp has a strong innovation capacity and aims to develop new therapies and stem cell products that can improve people's well-being. American Cryostem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Cryostem stock

EBIT per Share of American Cryostem is -0.05 USD in 2021.

EBIT per Share of American Cryostem changed from -0.02 USD to -0.05 USD, representing a 161.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share American Cryostem since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — American Cryostem

All Key Metrics — American Cryostem